HCD122 Mab

HCD122 is a fully human anti-CD40 antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases.  The antibody has a dual mechanism of action that involves blocking tumor cell growth and survival signals while recruiting immune effector cells to kill tumor cells through a process known as antibody-dependent cellular cytotoxicity (ADCC).

HCD122 is the first product candidate selected under the multi-product antibody development and commercialization agreement for the treatment of cancer announced by Chiron and us, and initiated in March of 2004.

HCD122 is an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration.

HCD122 was originally developed through a collaboration with Chiron.  Novartis is now developing this promising antibody candidate.